1/14
09:22 am
kura
Kura Oncology price target lowered to $20 from $25 at Leerink [Yahoo! Finance]
Low
Report
Kura Oncology price target lowered to $20 from $25 at Leerink [Yahoo! Finance]
1/13
11:08 am
kura
Kura Oncology (NASDAQ:KURA) was given a new $20.00 price target on by analysts at Leerink Partners.
Low
Report
Kura Oncology (NASDAQ:KURA) was given a new $20.00 price target on by analysts at Leerink Partners.
1/13
08:03 am
kura
Kura Oncology (NASDAQ:KURA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Kura Oncology (NASDAQ:KURA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
1/11
07:40 pm
kura
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones [Yahoo! Finance]
Low
Report
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones [Yahoo! Finance]
1/11
05:00 pm
kura
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Low
Report
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
1/9
07:38 pm
kura
How Komzifti Is Rewriting The Kura Oncology (KURA) Story For Analysts And Investors [Yahoo! Finance]
Medium
Report
How Komzifti Is Rewriting The Kura Oncology (KURA) Story For Analysts And Investors [Yahoo! Finance]
1/6
08:27 am
kura
Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer [Yahoo! Finance]
Low
Report
Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer [Yahoo! Finance]
1/5
07:30 am
kura
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/21
10:38 am
kura
Jim Cramer Discusses Kura Oncology as a Speculative Bet [Yahoo! Finance]
Medium
Report
Jim Cramer Discusses Kura Oncology as a Speculative Bet [Yahoo! Finance]
12/20
03:22 am
kura
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval [Yahoo! Finance]
Medium
Report
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval [Yahoo! Finance]
12/19
07:50 pm
kura
Is it time to get into biopharma player Kura Oncology? Jim Cramer digs in [CNBC]
Medium
Report
Is it time to get into biopharma player Kura Oncology? Jim Cramer digs in [CNBC]
12/8
10:30 am
kura
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Low
Report
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
12/6
09:21 pm
kura
Why The Narrative Around Kura Oncology Is Shifting After Komzifti's FDA Breakthrough [Yahoo! Finance]
Low
Report
Why The Narrative Around Kura Oncology Is Shifting After Komzifti's FDA Breakthrough [Yahoo! Finance]
12/5
07:21 am
kura
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/4
08:12 am
kura
Kura Oncology: A Cautious Buy [Seeking Alpha]
Low
Report
Kura Oncology: A Cautious Buy [Seeking Alpha]
12/3
07:02 pm
kura
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
Low
Report
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
12/3
08:32 am
kura
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
Medium
Report
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
12/2
06:42 pm
kura
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]
Medium
Report
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]
12/2
08:02 am
kura
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Low
Report
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
11/25
05:16 pm
kura
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
Low
Report
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
11/25
05:21 am
kura
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed [Yahoo! Finance]
Medium
Report
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed [Yahoo! Finance]
11/24
07:02 am
kura
Kura Oncology (NASDAQ:KURA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Kura Oncology (NASDAQ:KURA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/19
05:24 pm
kura
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript [Seeking Alpha]
Medium
Report
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript [Seeking Alpha]
11/17
04:36 pm
kura
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Komzifti™ (ziftomenib) [Yahoo! Finance]
Medium
Report
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Komzifti™ (ziftomenib) [Yahoo! Finance]
11/14
12:31 pm
kura
Kura Oncology (NASDAQ:KURA) had its price target raised by analysts at UBS Group AG from $14.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Kura Oncology (NASDAQ:KURA) had its price target raised by analysts at UBS Group AG from $14.00 to $16.00. They now have a "buy" rating on the stock.